Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine

The human epidermal growth factor receptor 2 (HER2) is overexpressed in 20% of breast carcinomas. Prior to the development of targeted therapies, HER2-positive breast cancer was associated with more aggressive disease and poor prognosis. Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate th...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Manag Res
Main Authors: Recondo, Gonzalo, de la Vega, Maximo, Galanternik, Fernando, Díaz-Cantón, Enrique, Leone, Bernardo Amadeo, Leone, José Pablo
Format: Artigo
Language:Inglês
Published: Dove Medical Press 2016
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4876844/
https://ncbi.nlm.nih.gov/pubmed/27274311
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S104447
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items